Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.15686 http://scihub22266oqcxt.onion/10.18632/oncotarget.15686 C5471062!5471062!28430640     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncotarget 2017 ; 8 (21): 35376-89 Nephropedia Template TP {{tp|p=28430640|t=2017. Epithelial-mesenchymal transition in prostate cancer: an overview |pdf=|usr=}}{{28430640}} gab.com Text Epithelial-mesenchymal transition in prostate cancer: an overview JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=28430640 #FOAvip Prostate cancer is a main urological disease associated with significant morbidity and mortality. Radical prostatectomy and radiotherapy are potentially curative for localized prostate cancer, while androgen deprivation therapy is the initial systemic therapy for metastatic prostate disease. However, despite temporary response, most patients relapse and evolve into castration resistant cancer.Epithelial-mesenchymal transition (EMT) is a complex gradual process that occurs during embryonic development and/or tumor progression. During this process, cells lose their epithelial characteristics and acquire mesenchymal features. Increasing evidences indicate that EMT promotes prostate cancer metastatic progression and it is closely correlated with increased stemness and drug resistance.In this review, we discuss the main molecular events that directly or indirectly govern the EMT program in prostate cancer, in order to better define the role and the mechanisms underlying this process in prostate cancer progression and therapeutic resistance. Twit Text FOAVip Epithelial-mesenchymal transition in prostate cancer: an overview ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=28430640 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28430640 #FOAvip English Wikipedia <ref>{{Cite pmid|28430640}}</ref> Epithelial-mesenchymal transition in prostate cancer: an overview #MMPMID28430640 Montanari M; Rossetti S; Cavaliere C; D'Aniello C; Malzone MG; Vanacore D; Franco RD; Mantia EL; Iovane G; Piscitelli R; Muscariello R; Berretta M; Perdonà S; Muto P; Botti G; Bianchi AAM; Veneziani BM; Facchini G Oncotarget 2017[May]; 8 (21): 35376-89 PMID28430640show ga Prostate cancer is a main urological disease associated with significant morbidity and mortality. Radical prostatectomy and radiotherapy are potentially curative for localized prostate cancer, while androgen deprivation therapy is the initial systemic therapy for metastatic prostate disease. However, despite temporary response, most patients relapse and evolve into castration resistant cancer.Epithelial-mesenchymal transition (EMT) is a complex gradual process that occurs during embryonic development and/or tumor progression. During this process, cells lose their epithelial characteristics and acquire mesenchymal features. Increasing evidences indicate that EMT promotes prostate cancer metastatic progression and it is closely correlated with increased stemness and drug resistance.In this review, we discuss the main molecular events that directly or indirectly govern the EMT program in prostate cancer, in order to better define the role and the mechanisms underlying this process in prostate cancer progression and therapeutic resistance. äEpithelial-mesenchymal transition in prostate cancer: an overview (epmc).pdf DeepDyve Pubget Overpricing